AN2 Therapeutics, Inc.
Total Trades
57
Buys
17
Sells
39
Largest Trade
$1M+
Insiders
14
Institutional Funds
21
Inst. Value
$1M+
Activist Filings
37
Insider Trades
| Insider | Title | Type | Value | Shares | Price | Date |
|---|---|---|---|---|---|---|
| Williams Sarah Joanne | Principal Accounti… | SELL | <$1K | 327 | $1.06 | Mar 5, 2026 |
| Day Lucy | CFO | SELL | $1K–$15K | 9K | $1.01 | Jan 8, 2026 |
| Prior Stephen David | Chief Strategy Off… | SELL | $1K–$15K | 6K | $1.01 | Jan 8, 2026 |
| Chanda Sanjay | Chief Development … | SELL | $1K–$15K | 9K | $1.01 | Jan 8, 2026 |
| Eizen Joshua M | See Remarks | SELL | $15K–$50K | 25K | $1.00 | Jan 8, 2026 |
| Eizen Joshua M | See Remarks | SELL | $1K–$15K | 3K | $1.14 | Nov 6, 2025 |
| Prior Stephen David | Chief Strategy Off… | SELL | <$1K | 765 | $1.14 | Nov 6, 2025 |
| Leonard Braden Michael | 10% Owner | SELL | $100K–$500K | 200K | $1.09 | Jun 16, 2025 |
| Easom Eric | CEO | BUY | $1K–$15K | 10K | $1.07 | Jun 3, 2025 |
| Leonard Braden Michael | 10% Owner | SELL | $1M+ | 2.5M | $1.13 | May 30, 2025 |
| FitzPatrick Margaret M | Director | BUY | $1K–$15K | 9K | $1.18 | May 29, 2025 |
| Day Lucy | CFO | SELL | $1K–$15K | 3K | $1.34 | Jan 8, 2025 |
| Chanda Sanjay | Chief Development … | SELL | $1K–$15K | 3K | $1.34 | Jan 8, 2025 |
| Prior Stephen David | Chief Strategy Off… | SELL | $1K–$15K | 2K | $1.34 | Jan 8, 2025 |
| Eizen Joshua M | See Remarks | SELL | $1K–$15K | 10K | $1.34 | Jan 8, 2025 |
| Readnour Robin Shane | Director | BUY | $100K–$500K | 75K | $1.41 | Nov 28, 2024 |
| Zakrzewski Joseph S | Director | BUY | $1K–$15K | 2K | $1.40 | Nov 27, 2024 |
| Readnour Robin Shane | Director | BUY | $100K–$500K | 200K | $1.07 | Nov 21, 2024 |
| Zakrzewski Joseph S | Director | BUY | $15K–$50K | 25K | $1.00 | Nov 20, 2024 |
| Easom Eric | CEO | BUY | $15K–$50K | 50K | $1.00 | Nov 19, 2024 |
| Zakrzewski Joseph S | Director | SELL | $1M+ | 100K | $19.11 | Jan 20, 2024 |
| Aziz Kabeer | Director | SELL | $1M+ | 100K | $19.65 | Jan 18, 2024 |
| Adjuvant Global Health Technology Fund, L.P. | 10% Owner | SELL | $1M+ | 100K | $19.65 | Jan 18, 2024 |
| Readnour Robin Shane | Director | SELL | $15K–$50K | 1K | $21.91 | Jan 17, 2024 |
| Readnour Robin Shane | Director | SELL | $50K–$100K | 4K | $21.93 | Jan 12, 2024 |
| Krause Kevin Michael | Chief Strategy Off… | SELL | $50K–$100K | 3K | $20.12 | Jan 4, 2024 |
| Krause Kevin Michael | Chief Strategy Off… | EXERCISE | $1K–$15K | 3K | $0.42 | Jan 4, 2024 |
| Easom Eric | CEO | SELL | $50K–$100K | 3K | $20.09 | Jan 4, 2024 |
| Adjuvant Global Health Technology Fund, L.P. | 10% Owner | SELL | $15K–$50K | 2K | $16.15 | Nov 16, 2023 |
| Aziz Kabeer | Director | SELL | $15K–$50K | 2K | $16.15 | Nov 16, 2023 |
| Aziz Kabeer | Director | SELL | $1M+ | 105K | $16.27 | Oct 3, 2023 |
| Adjuvant Global Health Technology Fund, L.P. | 10% Owner | SELL | $1M+ | 105K | $16.27 | Oct 3, 2023 |
| Adjuvant Global Health Technology Fund, L.P. | 10% Owner | SELL | $100K–$500K | 9K | $16.11 | Sep 29, 2023 |
| Aziz Kabeer | Director | SELL | $100K–$500K | 9K | $16.11 | Sep 29, 2023 |
| Aziz Kabeer | Director | SELL | $1K–$15K | 400 | $16.00 | Sep 15, 2023 |
| Adjuvant Global Health Technology Fund, L.P. | 10% Owner | SELL | $1K–$15K | 400 | $16.00 | Sep 15, 2023 |
| Adjuvant Global Health Technology Fund, L.P. | 10% Owner | SELL | $100K–$500K | 7K | $16.03 | Sep 8, 2023 |
| Aziz Kabeer | Director | SELL | $100K–$500K | 7K | $16.03 | Sep 8, 2023 |
| Adjuvant Global Health Technology Fund, L.P. | 10% Owner | SELL | $1K–$15K | 400 | $16.00 | Aug 25, 2023 |
| Aziz Kabeer | Director | SELL | $1K–$15K | 400 | $16.00 | Aug 25, 2023 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | BUY | $1M+ | 1.8M | $9.00 | Aug 22, 2023 |
| Easom Eric | CEO | BUY | $50K–$100K | 10K | $5.38 | May 16, 2023 |
| Easom Eric | CEO | SELL | $50K–$100K | 4K | $15.32 | Nov 15, 2022 |
| Easom Eric | CEO | SELL | $100K–$500K | 17K | $15.60 | Nov 10, 2022 |
| Easom Eric | CEO | SELL | $500K+ | 35K | $15.86 | Nov 8, 2022 |
| Easom Eric | CEO | SELL | $50K–$100K | 4K | $15.27 | Nov 3, 2022 |
| Easom Eric | CEO | SELL | $15K–$50K | 3K | $15.18 | Oct 29, 2022 |
| Easom Eric | CEO | SELL | $100K–$500K | 9K | $15.76 | Oct 27, 2022 |
| Easom Eric | CEO | SELL | $100K–$500K | 21K | $16.47 | Oct 25, 2022 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | BUY | $1K–$15K | 2K | $7.51 | Aug 5, 2022 |
Institutional Ownership
13F filings as of Dec 31, 2025 · 21 funds holding
| Fund | Shares | Value | Type |
|---|---|---|---|
| Almitas Capital LLC | 1.5M | $1M+ | SH |
| PFIZER INC | 715K | $500K+ | SH |
| Stonepine Capital Management, LLC | 628K | $500K+ | SH |
| Peapod Lane Capital LLC | 593K | $500K+ | SH |
| BANK OF NOVA SCOTIA | 459K | $500K+ | SH |
| BANK OF MONTREAL /CAN/ | 422K | $100K–$500K | SH |
| RENAISSANCE TECHNOLOGIES LLC | 339K | $100K–$500K | SH |
| MORGAN STANLEY | 229K | $100K–$500K | SH |
| GEODE CAPITAL MANAGEMENT, LLC | 209K | $100K–$500K | SH |
| STATE STREET CORP | 87K | $50K–$100K | SH |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 85K | $50K–$100K | SH |
| Squarepoint Ops LLC | 62K | $50K–$100K | SH |
| UBS Group AG | 57K | $50K–$100K | SH |
| JANE STREET GROUP, LLC | 18K | $15K–$50K | SH |
| Schonfeld Strategic Advisors LLC | 14K | $15K–$50K | SH |
| FEDERATED HERMES, INC. | 11K | $1K–$15K | SH |
| Valeo Financial Advisors, LLC | 10K | $1K–$15K | SH |
| VANGUARD GROUP INC | 7K | $1K–$15K | SH |
| BlackRock, Inc. | 645 | <$1K | SH |
| BNP PARIBAS FINANCIAL MARKETS | 303 | <$1K | SH |
Activist & 5%+ Owners
SC 13D/13G filings — investors holding 5%+ of outstanding shares
SC 13G · Feb 17, 2026
5.4%
3.0M shares
SC 13G/A · Feb 13, 2026
7.9%
2.2M shares
SC 13G · Nov 15, 2025
5.2%
1.4M shares
SC 13D/A · Jun 18, 2025
1.4%
427K shares
SC 13G · Jun 4, 2025
9.3%
2.8M shares
SC 13D/A · May 30, 2025
10.7%
3.2M shares
SC 13D · May 7, 2025
19.1%
5.7M shares
Adjuvant Global Health Technology Fund, L.P.
SC 13G/A · Mar 1, 2025
6.7%
2.0M shares
SC 13G/A · Feb 14, 2025
0.0%
0 shares
SC 13G/A · Feb 14, 2025
0.0%
0 shares
SC 13G/A · Feb 14, 2025
3.1%
927K shares
Frazier Life Sciences Public Fund, L.P.
SC 13G/A · Feb 14, 2025
0.0%
0 shares
SC 13G/A · Feb 13, 2025
6.2%
1.9M shares
SC 13G/A · Feb 13, 2025
19.2%
5.7M shares
Biotechnology Value Fund, L.P.
SC 13G/A · Nov 14, 2024
0.0%
0 shares
SC 13G/A · Nov 14, 2024
0.0%
6 shares
SC 13G/A · Nov 13, 2024
5.2%
1.6M shares
SC 13G/A · Aug 28, 2024
0.0%
0 shares
SC 13G/A · Aug 15, 2024
19.3%
5.7M shares
SC 13G/A · Aug 13, 2024
6.7%
2.0M shares
SC 13G · Aug 12, 2024
14.2%
4.2M shares
SC 13G · Jul 3, 2024
10.1%
3.0M shares
SC 13G/A · Feb 14, 2024
18.7%
5.6M shares
SC 13G/A · Feb 14, 2024
5.2%
6 shares
SC 13G · Feb 13, 2024
5.2%
157.2M shares
Janus Henderson Group plc EIN #00-0000000
SC 13G/A · Feb 12, 2024
4.3%
1.3M shares
SC 13G · Jul 25, 2023
6.6%
1.3M shares
Janus Henderson Group plc EIN #00-0000000
SC 13G · Jul 5, 2023
5.1%
1.0M shares
SC 13G/A · Feb 14, 2023
19.5%
3.8M shares
Biotechnology Value Fund, L.P.
SC 13G/A · Feb 14, 2023
4.4%
847K shares
SC 13G/A · Feb 14, 2023
6.9%
6 shares
SC 13G · Feb 13, 2023
7.0%
1.4M shares
SC 13G · Feb 13, 2023
5.4%
1.0M shares
Adjuvant Global Health Technology Fund, L.P.
SC 13G · Feb 10, 2023
11.3%
2.2M shares
SC 13G · Apr 8, 2022
19.6%
3.7M shares
SC 13G · Apr 8, 2022
7.1%
6 shares
Biotechnology Value Fund, L.P.
SC 13G · Apr 4, 2022
4.7%
875K shares